2022 Fiscal Year Final Research Report
Exploring innovative treatment avenues by harnessing the intricate regulation of pancreatic cancer stromal diversity
| Project/Area Number |
19K17429
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 53010:Gastroenterology-related
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2023-03-31
|
| Keywords | Meflin / がん抑制性線維芽細胞 / rCAF / pCAF / 膵がん / Cancer-Restraining CAF |
|---|
| Outline of Final Research Achievements |
There have long been conflicting views regarding the role of fibroblasts in the development and progression of cancer. While data suggesting that fibroblasts inhibit cancer were published for many years (Dr. Michael Stoker, University of Glasgow, UK, 1966), data suggesting that fibroblasts promote cancer were published in the late 1980s. In this study, we succeeded in identifying cancer-suppressing fibroblasts as proposed by Dr. Stoker, and showed that cancer-suppressing "cancer-restraining fibroblasts (r-CAFs)" may be present in each organ of the body.
|
| Free Research Field |
膵がん
|
| Academic Significance and Societal Importance of the Research Achievements |
約50年前にMicheal Stoker博士ら（グラスゴー大学）はポリオーマウイルスによって形質転換されたがん細胞の増殖が線維芽細胞によって抑制されることを示し、私達の体の線維芽細胞の本来の機能はがんの抑制性であることを提唱した。本研究は同博士の仮説を裏付けるものであり、線維芽細胞に関する今後の研究の発展に寄与するものである。
また、本研究によって膵臓がんのCAFの多様性の一部が明らかとなった。現在、がん促進性CAFをがん抑制性CAFに変換する新規治療法の開発が期待されており、本研究はそのための基盤を提供する。
|
